Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2008 08:05 ET | Source: BiPar Sciences

BiPar Sciences Presents Interim Phase 2 Results for PARP Inhibitor BSI-201 At San Antonio Breast Cancer Symposium

BRISBANE, Calif., Dec. 12, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing poly (ADP-ribose) polymerase (PARP) inhibitors as novel cancer...
December 10, 2008 09:30 ET | Source: BiPar Sciences

BiPar Sciences Receives 2008 Emerging Technology Award in Biotechnology

BRISBANE, Calif., Dec. 10, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, has received the 2008...
December 04, 2008 09:30 ET | Source: BiPar Sciences

BiPar Sciences to Present At the 31st CTRC-AACR Annual San Antonio Breast Cancer Symposium

BRISBANE, Calif., Dec. 4, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that the...
October 28, 2008 09:00 ET | Source: BiPar Sciences

BiPar Sciences' Lead Compound Selected as Top 10 Oncology Drug Candidate

BRISBANE, Calif., Oct. 28, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that its lead...
October 21, 2008 10:00 ET | Source: BiPar Sciences

BiPar to Present at the 7th Annual BIO Investor Forum in San Francisco

BRISBANE, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that John...
September 23, 2008 09:00 ET | Source: BiPar Sciences

BiPar Sciences Announces Senior Appointments in Corporate Development and Legal Functions

BRISBANE, Calif., Sept. 23, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, today announced that it has...